These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33491259)

  • 1. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
    Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A
    Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry.
    Lebwohl M; Strober B; Schrader A; Li AH; Eckmann T; Zhu B; Malatestinic WN; Birt J; Feely M; Blauvelt A
    Drugs Real World Outcomes; 2024 Sep; 11(3):451-464. PubMed ID: 38914857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Rheumatol Int; 2024 Oct; 44(10):2057-2066. PubMed ID: 39136784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
    Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Front Immunol; 2024; 15():1395968. PubMed ID: 38846940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort.
    Schots L; Soenen R; Blanquart B; Thomas D; Lambert J
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):698-710. PubMed ID: 36562700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
    Ohata C; Ohyama B; Katayama E; Nakama T
    J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
    Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
    Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease response and patient-reported outcomes among initiators of ixekizumab.
    Shahriari M; Harrison RW; Burge R; Lin CY; Malatestinic WN; Goldblum OM; McLean RR; Crabtree MM; O'Brien J; Grace EL; Murage MJ
    J Dermatolog Treat; 2022 May; 33(3):1538-1546. PubMed ID: 33267635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry.
    Wu JJ; Harrison RW; Zhu B; Goldblum OM; Malatestinic WN; Burge R; Murage MJ
    J Comp Eff Res; 2021 Feb; 10(2):157-167. PubMed ID: 33355477
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
    Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
    Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Psoriasis Psoriatic Arthritis; 2023 Jan; 8(1):7-10. PubMed ID: 39296950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
    Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D
    J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
    Lockshin B; Harrison RW; McLean RR; Crabtree MM; Konicek BW; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Burge RT
    Dermatol Ther (Heidelb); 2022 Dec; 12(12):2797-2815. PubMed ID: 36331713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.
    Wright S; Alloo A; Strunk A; Garg A
    J Am Acad Dermatol; 2020 Aug; 83(2):382-387. PubMed ID: 32289401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.
    Wang C; Torisu-Itakura H; Hanada T; Matsuo T; Cai Z; Osaga S; Aranishi T
    J Dermatolog Treat; 2023 Dec; 34(1):2229465. PubMed ID: 37403477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
    Kridin K; Schonmann Y; Solomon A; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
    J Dermatolog Treat; 2022 Jun; 33(4):2014-2020. PubMed ID: 33759683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
    Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
    J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Am Acad Dermatol; 2022 Jan; 86(1):68-76. PubMed ID: 34256035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.